INBUILD
2019
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
In 663 patients with non-IPF progressive fibrosing ILD, nintedanib slowed annual FVC decline compared with placebo.
Result
Primary endpoint: Annual rate of FVC decline
-80.8 vs -187.8 mL/year (difference 107 mL; p<0.001); effect consistent across UIP and non-UIP HRCT pattern.
- Subtopic
- Progressive fibrosing ILD
- Design
- Multicentre RCT
- Relevance
- Important: one of several pillars.
- Source
- Flaherty KR, et al. N Engl J Med. 2019;381(18):1718-1727.doi 10.1056/NEJMoa1908681
Discussion & critique
Broadened nintedanib's indication beyond IPF to any progressive fibrosing ILD.